Effect of Actonel on Periodontal Health of Postmenopausal Women

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00594334

Enrollment

Registered

2008-01-15

Start date

2008-01-31

Completion date

2011-01-31

Last updated

2022-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Disease

Keywords

osteopenia, periodontitis

Brief summary

Hypothesis: Women who use Actonel (risedronate) for osteopenia will show beneficial periodontal effects.

Detailed description

Women who use Actonel for osteopenia will show beneficial attachment loss, alveolar bone height and morphology as compared to those who do not when oral hygiene is corrected for.

Interventions

DRUGRisedronate

Weekly Risedronate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

40 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Osteopenia * Postmenopausal

Exclusion criteria

* Male * Diabetes

Design outcomes

Primary

Measure	Time frame
Periodontal alveolar bone changes	one year

Secondary

Measure	Time frame
Periodontal attachment levels	one year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026